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Abstract
Background: Lung transplant recipients with serious illness may benefit from but rarely receive specialty
palliative care (SPC) services. Transplant pulmonologists’ views of SPC may be key to understanding SPC
utilization but have not been well characterized.
Objectives: (1) To understand how transplant pulmonologists view SPC and decide to refer transplant recipients
and (2) to identify unique aspects of lung transplantation that may influence referral decisions.
Design: We conducted semistructured interviews with transplant pulmonologists at nine geographically diverse
high-volume North American transplant centers with SPC services. A multidisciplinary team analyzed inter-
view transcripts using constant comparative methods to inductively develop and refine a coding framework
related to SPC views and referral decisions.
Results: We interviewed 38 transplant pulmonologists; most (36/38) had referred lung transplant recipients to
SPC. Participants described SPC as a medical specialty that aims to improve quality of life and distinguished
SPC from hospice care, which was considered end-of-life care. Participants who viewed transplant as a tem-
porary solution (n = 17/38, 45%) described earlier utilization of SPC alongside disease-directed therapies,
whereas those who viewed transplant as survival-focused (n = 21/38, 55%) described utilization of SPC after
disease-directed therapies were exhausted. Concerns about one-year survival metrics and use of addicting
medications for symptom palliation were barriers to referral.
Conclusions: Transplant pulmonologists’ SPC referral practices may be related to their views of lung trans-
plantation. Optimizing use of SPC in lung transplantation will require improving communication between
transplant pulmonology and SPC to ensure a collaborative effort toward patient-centered goals while addressing
unique barriers to SPC referral.
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Lung transplantation is an increasingly commontherapy for patients with end-stage lung disease.1 Lung
transplant recipients frequently experience declines in qual-
ity of life because of transplant-related complications, espe-
cially chronic allograft rejection and face foreshortened
survival.2–7 Transplant recipients with serious illness may
benefit from specialty palliative care (SPC), but evidence
suggests SPC is rarely received.2,8,9 Barriers to SPC referral
for lung transplant recipients are poorly understood.8,9
How transplant pulmonologists view SPC may be key to
understanding SPC utilization. Previous work suggests that
oncologists’ who view SPC as end-of-life care are less likely
to refer patients.10–13 Little is currently known about how
transplant pulmonologists view SPC. Two survey studies of
lung transplant providers suggest that perceptions of pallia-
tive care as end-of-life care, precluding other treatments, or
contradictory to the goals of transplant may be barriers to
referral.9,14 Neither study, however, assessed the reasons
underlying these perceptions.
Understanding how transplant pulmonologists perceive
SPC and decide to refer transplant recipients to SPC is nec-
essary to understand post-transplant SPC utilization. In this
study we sought to understand how transplant pulmonolo-
gists view SPC and decide to refer transplant recipients to
SPC, focusing on unique aspects of transplantation that may
influence SPC utilization. Because little is known about this
topic, we chose a qualitative approach suited to addressing
issues of what, how, and why.15 Our goal was to provide a
framework for understanding post-transplant SPC utilization




We conducted qualitative, in-depth semistructured inter-
views to allow flexibility in exploring transplant pulmonol-
ogists views of SPC and decisions to refer lung transplant
recipients to SPC.
Sample and recruitment
Participants were transplant pulmonologists at high-
volume centers performing >40 lung transplants a year. We
used purposive sampling to recruit participants from geo-
graphically diverse centers with inpatient and outpatient
SPC consult services: University of Toronto, University of
Washington, University of Pittsburgh Medical Center, Duke
University, University of California at San Francisco, Uni-
versity of Loyola, University of Pennsylvania, Brigham and
Women’s Hospital, and Washington University in St. Louis.
Eligible participants were attending transplant pulmonolo-
gists who care for transplant recipients. Potential participants
were identified with the assistance of local colleagues and
initially contacted by email. Follow-up to schedule inter-
views was conducted through a combination of email and
direct contact by local colleagues. Participants provided
informed consent either in person or electronically. The Uni-
versity of Pittsburgh Institutional Review Board approved
this study.
Data collection
All participants completed a semistructured in-depth inter-
view followed by a brief demographic survey. Interviews were
conducted either in-person or through telephone between
October 2017 and March 2018 by an investigator trained in
using standard semistructured, in depth interviewing tech-
niques (E.P.N.). The in-depth interview guide focused on three
domains: understanding of SPC, deciding to refer transplant
recipients to SPC, and unique aspects of transplantation affect-
ing referral. Participants were asked to define SPC (Can you
define SPC for me?) and explain the relationship between SPC
and hospice care (In your mind, what is the relationship between
SPC and hospice?). Questions were open-ended and nonleading,
with follow-up probes used to elicit description of individual
experiences and encourage participants to reflect on their own
patients. Participants were also asked to discuss hypothetical
patients presented in brief vignettes because sometimes asking
participants to reflect on their own patients is sensitive and rel-
evant issues can be better explored using a hypothetical pa-
tient.16,17 The full interview guide is available in Supplementary
Data. Interviews were audio recorded, transcribed verbatim, and
conducted until thematic saturation was reached, meaning no
new themes emerged from additional interviews.
Data analysis
Data analysis was performed iteratively and the coding
framework was developed using the constant comparative
method.18,19 Using this approach, four investigators with
multidisciplinary backgrounds (E.N., D.K., M.A.D., and
Y.A.S.) reviewed a subset of transcripts and inductively de-
veloped a codebook describing transplant pulmonologists
views of SPC and factors influencing SPC referral. Through
multiple cycles of coding, comparison, and refinement codes
were classified, grouped, and refined into themes. All dis-
agreements were discussed and resolved by group consensus.
An investigator trained in qualitative analysis (E.N.) applied
the final coding framework to all transcripts. A second in-
vestigator ( J.F.) coded 30% of transcripts with comparison to
ensure full intercoder agreement between coders with dis-
agreements resolved by consensus. As a final step we con-
ducted member checking by sending synthesized results to a
subset of participants who provided feedback on the relevance
of the results to their experiences.20 The qualitative data
analysis software NVIVO (NVIVO 11 for Macintosh; QSR
International) facilitated analysis. Demographic data were
summarized using counts, percents, means, and medians.
Results
Among 61 transplant pulmonologists contacted for par-
ticipation, 38 completed interviews with participation from
all 9 sites. Demographic characteristics of participants are
listed in Table 1. Qualitative analysis yielded three major
themes emerged related to study aims.
Defining SPC
Transplant pulmonologists described SPC as an approach
to care for patients with chronic or advanced medical disease
that aims to improve quality of life (Table 2).
Nearly all participants (n = 34/38, 89%) described SPC as
providing symptom management. Symptoms for which they















































felt SPC offered benefit for included pain, anxiety, and
breathlessness. One participant described how SPC could
help a range of symptoms that differ from patient to patient:
‘‘it’s patient dependent thing.(SPC could help) any symp-
toms associated with their underlying disease process which
could include pain or anxiety or dyspnea or discomfort re-
lated to treatment.’’
A third of participants (n = 12/38, 32%) described SPC as
providing psychological or spiritual support. Some partici-
pants described how support provided by SPC was important
for both transplant recipients and their caregivers. As one
participant explained, SPC can be for the patient and ‘‘for the
family or the loved ones who take care of the patient. when
somebody goes for a lung transplant there’s only one patient,
but everybody who is taking care of a patient basically has to
have the same support.’’
About half of participants (n = 20/38, 53%) described SPC
as helping to identify patient preferences or discussing goals
of care. One participant described SPC as a specialty that
‘‘focuses on identifying patient preferences and trying to help
patients understand how to receive treatment that is consis-
tent with their wishes.’’
Virtually all participants (n = 37/38, 97%) described SPC
as providing more than hospice, which was described as
end-of-life care and a component of the services that SPC
provides (Table 2). For example, one participant described
SPC and hospice as existing ‘‘as a continuum.symptom
control in the setting of aggressive medical care all the way
to the other end of the spectrum which is educating and
initiating Hospice Care.’’
Views of lung transplantation
Participants expressed two differing views of lung trans-
plantation (Table 3). Approximately half of participants
(n = 17/38, 45%) described transplant as temporary solution
for an incurable disease or exchange of problems with un-
certain outcomes. One compared transplantation to a chronic
disease, stating that ‘‘essentially we are dealing with a
chronic disease.we’re exchanging one set of problems for
another.getting a lung transplant doesn’t mean you are
going to live forever.it’s not a perfect fix.’’
Other participants (n = 21/38, 55%) described transplant
as therapy focused on treatment and survival. As one par-
ticipant described, ‘‘so much of the push in transplant is to
treat, to beat the odds.transplant itself is salvage therapy
and then when the graft starts failing you do all sorts of
things for salvage therapy.’’ Several felt a treatment-focused
mindset was shared by transplant recipients. According to
one participant, ‘‘our philosophy and I think most patients’
philosophy is that once they get a transplant they’re gonna
want to do everything they can to make it last as long as
possible.’’
Participants’ views of transplantation were associated
with different SPC referral practices (Table 3). Those
describing transplant as a temporary solution tended to
Table 1. Demographic Characteristics of Participant
Transplant Pulmonologists
Characteristic N = 38
Age, years, mean (–SD) 43.3 (–7.1)






Half days per week in clinic, mean (–SD) 2 (–1)
Palliative Care Fellowship 3% (1)
Have referred a transplant recipient to SPC 95% (36)
IQR, interquartile range; SD, standard deviation; SPC, specialty
palliative care.





‘‘I would define it as providing the alleviation of suffering.aspects of suffering that
patients can go through physically, emotionally, psychologically (palliative care)
can help with’’
Support for patients and
caregivers: 12/38 (32%)
‘‘Palliative care is an approach to managing symptoms for patients with non-curable
illnesses um, at any point along their disease trajectory. it also can deal with it




of care: 20/38 (53%)
‘‘Palliative care is more encompassing of, of the bigger picture of goals of care, you
know, not even just at end of life.how do people want things to look as they get
sicker, if they have a chronic illness, or at the end of life.’’
Relationship between SPC and hospice care
Hospice is a component
of SPC and is end-of-life
care: 37/38 (97%)
‘‘I think that hospice is an avenue that palliative care can use to facilitate a very
comfort-focused approach to the end of life. Palliative care can obviously also
include a lot of approaches at different stages of life that don’t necessarily result in
dying.Hospice would be a tool in the palliative care armory’’
‘‘I do view hospice as kind of equivalent with end of life.For patients that aren’t
end of life and wouldn’t be considered for hospice there would still be a role for
palliative care. So like in a Venn Diagram there’d be some overlap for the end of
life, but not necessarily for everybody’’















































describe referring to SPC while pursuing disease-directed
therapies. One participant described how SPC could be
used, ‘‘not just for end of life type discussions and plan-
ning.but also to help us keep people comfortable who are
dealing with either difficulties immediately after surgery.or
down the road with medical complications.’’ These partici-
pants often reported referring to SPC after the onset of
chronic rejection, which they described as irreversible with
an uncertain course and significant symptoms. They de-
scribed how SPC could help with symptom management
and coping. As one participant stated about patients with
chronic rejection: ‘‘in an environment of uncertainty.how
you cope with all those symptoms and how you cope psy-
chologically and physically with that, that is the biggest
benefit. We are riding along in a roller coaster, let’s try to
make the ride a little bit easier.’’ Several participants also
described how SPC could help optimize patients for re-
transplantation. Discussing a hypothetical patient, one
physician commented: ‘‘if we want her to be a good can-
didate for a re-transplant. psychologically and medically
stable and optimized to go through another stressful event
and to wait on the waiting list however long that might
take.that would make me very inclined to refer.’’
Participants describing transplantation as treatment fo-
cused on survival tended to refer to SPC once disease-
directed therapies were exhausted. As one explained:
I refer once we’ve exhausted all therapies that I anticipate
that might help the lung function stabilize and the lung func-
tion continues to deteriorate . oftentimes recipients think
things are going in a bad direction but then you can turn them
around. So I don’t refer to Palliative Care until.in spite of
everything we’ve done, the graft is continuing to fail.
Re-transplantation was a common barrier to referral. Some
described re-transplantation and SPC as different treatment
paths or different goals. As one explained,
If she was a candidate for a re-transplant I wouldn’t pursue
Palliative Care. I view the two as sort of not convergent paths.
If you’re gonna have a re-transplant, the path is a different
one than if you’re gonna be in Palliative Care, where things
like pulmonary rehab and so on are maybe not quite as im-
portant or not necessary.
Table 3. Transplant Pulmonologists Views of Lung Transplantation and Associated
Specialty Palliative Care Referral Practices
Comments
View of transplantation as a temporary solution and associated SPC referral practices (n = 17/38, 45%)
Transplant is a temporary solution
or an exchange of problems
‘‘(transplant is) definitely its own interesting specialty in that patients come in
dying and eventually they die all over again.they’re facing death and then
we try to save them, but they will face death again and we all know it’’
‘‘transplant has a 5 year survival of 50–60% and that’s a one year survival of
85% and that’s very similar to most cancers so almost, almost every patient
I see has a terminal diagnosis even with or without transplant’’
Referring to SPC alongside
disease-directed therapies
‘‘we still have treatment options.but I think palliative care might be able to
help her with symptom control.I would be referring her for that one end
of the spectrum where they’d be complimenting the aggressive therapy that
we’d be providing’’
SPC helps patients cope with
chronic rejection
‘‘chronic rejection is such a devastating diagnosis . and makes me more
likely to refer (to palliative care), not necessarily for the physical symptom
management, but also to talk about and process what that means for her life
trajectory’’
SPC helps prepare patients for
transplantation
‘‘We can use (palliative care) in two different ways.because we are going to
relist her for transplant and try to manage her symptoms or try to make her
more aware of not any other option.and try to maximize her well-being’’
View of transplantation as survival focused and associated SPC referral practices (n = 21/38, 55%)
Transplant is focused on treatment
and survival
‘‘most patients have gotten to a mindset where they’re undergoing a very
major surgery certainly with potential for a lot of good, but also potential
for complications that for the most part, across the board, I’d say most of
our patients are very aggressive about trying to get things to work’’
‘‘(Transplant is an) extremely limited one time offer in that that lung, if it
goes to one patient and can’t go to another. So the sense within the medical
community is that we need to do everything we can to help this person
survive through a transplant’’
Referring to SPC once disease-directed
therapies are exhausted
‘‘I don’t see an acute need (for SPC).she’s being aggressively treated with
therapies that could potentially either halt or reverse this process.before
saying that we’ve exhausted all treatment modalities’’
SPC and re-transplantation are
different paths
‘‘I’ve never referred someone that is a re-transplantation candidate to
palliative care.that’s just not the pathway . there’s an immediate
transition made to re-transplantation and so that idea of palliative care
probably gets, like, swept by the wayside.logistically there’s not a box
that needs to be checked for palliative care’’















































For others, the intense treatment approach required for re-
transplantation precluded consideration of SPC. As one de-
scribed, ‘‘we probably would be so focused on maintaining
her physical functioning, other good organ function, keeping
her optimal, that (SPC) probably would just be crowded out
and wouldn’t even enter the thought process.’’
Unique barriers to SPC referral
Over a third of participants (n = 14/38, 37%) reported re-
ferral was less likely in the first post-transplant year (Table 4).
Many expressed concern that referral could increase one-year
mortality, a key metric by which programs are judged. As one
explained, SPC referral is:
harder when you have a fresher transplant.certainly
within the first year when you’re really worried about its
impact on outcomes.(programs are) judged by how our ex-
pected outcomes match with our observed outcomes. And if we
don’t meet those criteria or they’re significantly off then we’re
at risk of.being examined and audited.
Others felt the focus on one-year survival deterred dis-
cussion of SPC even when patients might benefit. One
participant explained the first post-transplant year is: ‘‘such
a huge benchmark for a program that I think it deters
providers and patients (from discussing SPC).it does
impede sometimes early referral, particularly in patients
who don’t do well and we know that they won’t do well, very
early on.’’
Another barrier to referral mentioned by about a third of
participants (n = 12/38, 32%) was the potential use of opioids
and benzodiazepines for symptom palliation (Table 4). Several
participants had concerns that SPC providers would prescribe
opioids, which some centers consider inappropriate for re-
transplant candidates. As one explained if ‘‘the wish is actually
to get to lung transplant.we’re all set before transplant on
medications. opioids to palliate dyspnea are not medications
that we can really use a whole lot because we’re trying to keep
them mobile and awake and engaged.’’ Others expressed
concern that opioids could cause harm to patients with ad-
vanced lung disease. One participant discussed, ‘‘overzealous
narcotic prescribing on the part of Palliative Care.(they)
recommended relatively high narcotic doses and I was worried
that (could) lead to a respiratory arrest.’’ Finally, several
expressed worry about using opioids or benzodiazepines early
in the course of chronic rejection because patients could be-
come addicted. As one explained ‘‘opioids, benzodiazepine,
anything that can create some addiction.I feel that they (SPC
providers) may start more liberally using them than what we
use. So there is a little bit of a conflict of how much and how
soon you will start certain therapies.’’
Discussion
Transplant pulmonologists’ views of SPC may be key to
understanding post-transplant SPC utilization. In this multi-
center study, we found that transplant pulmonologists de-
fine SPC as a specialty focused on improving quality of life
and distinguish SPC from hospice. Transplant pulmonolo-
gists who viewed transplant as a temporary solution to
an incurable disease described earlier utilization of SPC
Table 4. Emphasis on One-year Outcomes and Concerns About Potentially Addicting Medications
Are Unique Barriers to Referral in Lung Transplantation
Comments
Emphasis on one-year outcomes (n = 14/38, 37%)
Emphasis on one-year survival
makes SPC referral less likely
‘‘I think there’s a real push for programs to.improve their statistics such as
more than 5 year survival and so if patients are sick and in need of palliative
care and they’re prior to their, especially, one year survival mark I think
there’s a tendency to try to do everything possible to focus on patient survival
and I think sometimes we tend to overlook focusing on patient’s comfort’’
‘‘I think that there is a barrier in the way that transplant success is judged with
like one-year mortality being incredibly important, that if somebody has a
rough first year, I think there is a hesitation to involve palliative care because I
think the transplant team in general doesn’t want to hear that we should stop’’
Concern about use of opioids and benzodiazepines for symptom palliation (n = 12/38, 32%)
Compatibility with re-transplantation
candidacy
‘‘if we are focusing on anxiety and pain and if we’ve got someone with really
poor prognosis.use of narcotic medications and benzodiazepines is common,
and if we’re evaluating someone for re-transplantation or considering re-
transplantation, we would not want those patients to use those medications
while they’re still under evaluation or in preparation for a second transplant’’
Concern about adverse events due
to medications
‘‘maybe another reason that I wouldn’t (refer to SPC) is that we often think
about narcotics and things like that to try and ease, to ease work of breathing,
lessening dyspnea, while at the same time could depending on the dose cause
worsening symptoms or worsening CO2 retention and things like in some of
our patients’’
Concern about addiction ‘‘I would worry about her being started on opioids kind of early in her disease
process (chronic rejection).I’m obviously mindful of some of the negative
aspects of opioids use.I would worry a little that they may have quite a long
life ahead of them still and that they might get dependent on opioids if that’s
chosen as the primary way of managing their shortness of breath’’















































alongside disease-directed therapies, whereas those who
viewed transplant as survival focused described utilization
of SPC after disease-directed therapies were exhausted. We
also identified concerns about one-year survival outcomes
and use of opioids and benzodiazepines as unique barriers to
SPC referral.
Previous studies of physicians’ views of SPC in other
populations suggest physicians who equate SPC with hospice
or end-of-life care may be less likely to refer patients to
SPC.10,12,21,22
A decade ago a multicenter study of 40 lung transplant
providers found that many considered palliative care equiv-
alent to end-of-life care.9 In contrast, transplant pulmonolo-
gists in our study distinguished between SPC and hospice
care and viewed hospice as only one component of the more
broad scope of SPC. Our results suggest that transplant pul-
monologists’ SPC referral practices may be related to factors
other than their understanding of SPC.
Transplant pulmonologists in our study described two dis-
tinct views of transplant and two different SPC referral prac-
tices. Participants describing transplantation as a temporary
solution reported referring to SPC alongside disease-directed
therapies, whereas those describing transplantation as survival-
focused reported referring after disease-directed therapies were
exhausted. One potential explanation is that transplant pul-
monologists’ beliefs about appropriate post-transplant treat-
ments and goals may influence whether or when SPC referral is
offered. Previous work in other settings illustrating associa-
tions between physician beliefs and treatment options offered
to patients support this interpretation.23–27 Our finding that
some transplant pulmonologists view transplantation as fo-
cused on survival and incompatible with SPC is supported by
previous studies. First, an international survey of 158 lung
transplant providers perceptions of SPC referral barriers for
transplant candidates found that many perceived the goals of
transplantation and SPC to be contradictory.14 Second, a small
qualitative study of transplant recipients’ caregivers and
transplant pulmonologists suggested that re-transplantation
was the sole focus of care until disease-directed therapies were
exhausted.28 Although previous studies do suggest that trans-
plant recipients prioritize graft survival, understanding the
extent to which physicians’ views of transplantation and SPC
are shared by transplant recipients is an important area for
future investigation.29–33
We also identified two unique barriers to SPC referral in
lung transplantation. First, concerns about decreasing one-
year survival rates were described as a reason not to refer to
SPC. Risk-adjusted one-year survival is used to judge
transplant program quality, and lower than expected survival
rates can lead to loss of program accreditation.34,35 Our re-
sults suggest that this metric may discourage SPC referral,
despite no evidence that SPC affects mortality.36 Focus on
one-year survival also suggests an implicitly agreed upon
approach to post-transplant care akin to surgical ‘‘buy-
in.’’37,38 ‘‘Buy-in’’ is the informal negotiation of a commit-
ment where surgeons agree to take risk and operate, and
patients agree to the postoperative care surgeons deem nec-
essary. In lung transplantation, this implicit negotiation may
mean that programs undertake the risks of transplantation and
patients agree to care to achieve one-year survival. To our
knowledge, this is the first study to identify this concept in
lung transplantation.
A second barrier to SPC referral was concerns about use of
opioids and benzodiazepines for symptom palliation. Use of
chronic opioids is a considered a contraindication to re-
transplantation at some centers. To our knowledge, this is the
first study to identify this as a barrier to SPC referral. Con-
cerns about respiratory depression and addiction are known
barriers to using opioids for refractory breathlessness for
patients with advanced chronic obstructive pulmonary dis-
ease.39–43 Our results suggest these concerns are shared by
transplant pulmonologists and a barrier to SPC referral. One
center has successfully used low-dose opiates to manage
breathless pretransplantation.44,45 Other studies suggest
chronic post-transplant opioid prescription may be associated
with mortality.46,47 Finally, concerns about addiction may
also reflect the impact of the opioid epidemic and increased
understanding of the long-term risks of these medications in
populations without serious illness. Better communication
between SPC and transplant providers about requirements for
transplant eligibility and the benefits of these medications
may help overcome this barrier.
Our study has limitations. We attempted to recruit a di-
verse sample of participants from large transplant volume
centers; our findings may not reflect the views of partici-
pants from lower volume transplant centers, centers that do
not have SPC services, or centers outside North America.
Although we had a participation rate similar to other stud-
ies, our results may not reflect views of transplant pulmo-
nologists who chose not to participate.12 Our results may
not be applicable to the pretransplant setting, which should
be a focus of further study. Finally, given the qualitative
nature of this study, our finding of associations between
different views of transplant and SPC referral practices are
exploratory and should be used to inform future quantitative
work.
In conclusion, transplant pulmonologists distinguish be-
tween SPC and hospice care and describe two different views
of transplantation that may be related to different SPC re-
ferral practices after lung transplantation. Further work is
needed to understand transplant recipients’ views of lung
transplantation and perceptions of SPC, to understand how
SPC providers view their roles in caring for transplant re-
cipients, to define the scope of practice for SPC in lung
transplantation, and address issues of access and workforce
shortages. Optimizing use of SPC in lung transplantation will
require an improving communication between transplant and
SPC providers to ensure a collaborative effort to achieve
transplant candidates’ and recipients’ goals.
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